Helmholtz Gemeinschaft


Browse by Research Team

Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Source
Jump to: 2022 | 2021 | 2020


Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner, H. and Weber, D. and Krzykalla, J. and Fiedler, W. and Wulf, G.G. and Salih, H.R. and Lübbert, M. and Kühn, M. and Schroeder, T. and Salwender, H. and Götze, K.S. and Westermann, J. and Fransecky, L. and Mayer, K. and Hertenstein, B. and Ringhoffer, M. and Tischler, H.J. and Machherndl-Spandl, S. and Schrade, A. and Paschka, P. and Gaidzik, V.I. and Theis, F. and Thol, F.R. and Heuser, M. and Schlenk, R.F. and Bullinger, L. and Saadati, M. and Benner, A. and Larson, R.A. and Stone, R.M. and Döhner, K. and Ganser, A.
Blood Advances 6 (18): 5345-5355. 27 September 2022

Comorbidities rather than older age define outcome in adult patients with tumors of the Ewing sarcoma family.
Striefler, J.K. and Schmiester, M. and Brandes, F. and Dörr, A. and Pahl, S. and Kaul, D. and Rau, D. and Dobrindt, E.M. and Koulaxouzidis, G. and Bullinger, L. and Märdian, S. and Flörcken, A.
Cancer Medicine 11 (17): 3213-3225. September 2022

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N. and Jahn, E. and Saadati, M. and Bullinger, L. and Larson, R.A. and Ottone, T. and Amadori, S. and Prior, T.W. and Brandwein, J.M. and Appelbaum, F.R. and Medeiros, B.C. and Tallman, M.S. and Ehninger, G. and Heuser, M. and Ganser, A. and Pallaud, C. and Gathmann, I. and Krzykalla, J. and Benner, A. and Bloomfield, C.D. and Thiede, C. and Stone, R.M. and Döhner, H. and Döhner, K.
Leukemia 36 (9): 2218-2227. September 2022

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K. and Schmalbrock, L.K. and Jung, P. and Bumeder, I. and Kiewe, P. and Hecker, J.S. and Verbeek, M. and Westermann, J. and Bullinger, L. and Keller, U. and Bassermann, F. and Krönke, J. and Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

Precision medicine in myeloid malignancies.
Westermann, J. and Bullinger, L.
Seminars in Cancer Biology 84 : 153-169. September 2022

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Zhai, Y. and Singh, P. and Dolnik, A. and Brazda, P. and Atlasy, N. and Del Gaudio, N. and Döhner, K. and Döhner, H. and Minucci, S. and Martens, J. and Altucci, L. and Megchelenbrink, W. and Bullinger, L. and Stunnenberg, H.G.
Molecular Cancer 21 (1): 166. 19 August 2022

The landscape of genetic aberrations in myxofibrosarcoma.
Takeuchi, Y. and Yoshida, K. and Halik, A. and Kunitz, A. and Suzuki, H. and Kakiuchi, N. and Shiozawa, Y. and Yokoyama, A. and Inoue, Y. and Hirano, T. and Yoshizato, T. and Aoki, K. and Fujii, Y. and Nannya, Y. and Makishima, H. and Pfitzner, B.M. and Bullinger, L. and Hirata, M. and Jinnouchi, K. and Shiraishi, Y. and Chiba, K. and Tanaka, H. and Miyano, S. and Okamoto, T. and Haga, H. and Ogawa, S. and Damm, F.
International Journal of Cancer 151 (4): 565-577. 15 August 2022

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen, A. and Ben Hamza, A. and Welters, C. and Dietze, K. and Bullinger, L. and Rahn, H.P. and Hartmann, S. and Hansmann, M.L. and Hansmann, L.
Cancer Immunology Immunotherapy 10 August 2022 (In Press)

Unified classification and risk-stratification in Acute Myeloid Leukemia.
Tazi, Y. and Arango-Ossa, J.E. and Zhou, Y. and Bernard, E. and Thomas, I. and Gilkes, A. and Freeman, S. and Pradat, Y. and Johnson, S.J. and Hills, R. and Dillon, R. and Levine, M.F. and Leongamornlert, D. and Butler, A. and Ganser, A. and Bullinger, L. and Döhner, K. and Ottmann, O. and Adams, R. and Döhner, H. and Campbell, P.J. and Burnett, A.K. and Dennis, M. and Russell, N.H. and Devlin, S.M. and Huntly, B.J.P. and Papaemmanuil, E.
Nature Communications 13 (1): 4622. 8 August 2022

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy.
Ihlow, J. and Gross, S. and Busack, L. and Flörcken, A. and Jesse, J. and Schwarz, M. and Neuendorff, N.R. and von Brünneck, A.C. and Anagnostopoulos, I. and Türkmen, S. and Blau, I.W. and Burmeister, T. and Horst, D. and Bullinger, L. and Westermann, J.
Haematologica 107 (8): 1773-1785. August 2022

Application of precision medicine in clinical routine in haematology - challenges and opportunities.
Wästerlid, T. and Cavelier, L. and Haferlach, C. and Konopleva, M. and Fröhling, S. and Östling, P. and Bullinger, L. and Fioretos, T. and Smedby, K.E.
Journal of Internal Medicine 292 (2): 243-261. August 2022

Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls.
Winkelmann, N. and Schwarz, M. and Hildebrandt, B. and Henke, O. and Bullinger, L. and Na, I.K. and Stintzing, S. and le Coutre, P.
eJHaem: The Official Journal of the British Society for Haematology 3 (3): 949-953. August 2022

Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo, M.F. and Welters, C. and Rosenberger, L. and Leisegang, M. and Dietze, K. and Pircher, C. and Penter, L. and Gary, R. and Bullinger, L. and Takvorian, A. and Moosmann, A. and Dornmair, K. and Blankenstein, T. and Kammertöns, T. and Gerbitz, A. and Hansmann, L.
Cytotherapy 24 (8): 818-826. August 2022

The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
Viñado, A.C. and Calvo, I.A. and Cenzano, I. and Olaverri, D. and Cocera, M. and San Martin-Uriz, P. and Romero, J.P. and Vilas-Zornoza, A. and Vera, L. and Gomez-Cebrian, N. and Puchades-Carrasco, L. and Lisi-Vega, L.E. and Apaolaza, I. and Valera, P. and Guruceaga, E. and Granero-Molto, F. and Ripalda-Cemborain, P. and Luck, T.J. and Bullinger, L. and Planes, F.J. and Rifon, J.J. and Méndez-Ferrer, S. and Yusuf, R.Z. and Pardo-Saganta, A. and Prosper, F. and Saez, B.
Leukemia 36 (8): 1969-1979. August 2022

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.
Grasedieck, S. and Cabantog, A. and MacPhee, L. and Im, J. and Ruess, C. and Demir, B. and Sperb, N. and Rücker, F.G. and Döhner, K. and Herold, T. and Pollack, J.R. and Bullinger, L. and Rouhi, A. and Kuchenbauer, F.
Haematologica 107 (8): 1758-1772. August 2022

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Zaleska, J. and Kwasnik, P. and Paziewska, M. and Purkot, Jo. and Szabelak, A. and Jurek, M. and Masny, N. and Dziatkiewicz, I. and Pronobis-Szczylik, B. and Piebiak, A. and Szymczyk, A. and Jarosz-Chudzik, K. and Bolkun, L. and Kozlowska, K. and Piszcz, J. and Subocz, E. and Halka, J. and Bator, M. and Kalicinska, E. and Wrobel, T. and Usnarska-Zubkiewicz, L. and Rybka, J. and Deren-Wagemann, I. and Szyca-Smieszniak, M. and Dybko, J. and Hus, I. and Pula, B. and Cichocka, E. and Rymko, M. and Zdunczyk, D. and Ziarkiewicz, M. and Basak, G.W. and Bullinger, L. and Giannopoulos, K.
International Journal of Cancer 13 July 2022 (In Press)

Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity.
Feldkamp, J.D. and Vetter, V.M. and Arends, C.M. and Lang, T.J.L. and Bullinger, L. and Damm, F. and Demuth, I. and Frick, M.
Haematologica 107 (7): 1703-1708. July 2022

Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma.
Schmiester, M. and Maier, R. and Riedel, R. and Durek, P. and Frentsch, M. and Kolling, S. and Mashreghi, M.F. and Jenq, R. and Zhang, L. and Peterson, C.B. and Bullinger, L. and Chang, H.D. and Na, I.K.
Gut microbes 14 (1): e2081475. 29 May 2022

Paired donor and recipient immunophenotyping in allogeneic hematopoietic stem cell transplantation: a cellular network approach.
Wittenbecher, F. and Lesch, S. and Kolling, S. and Blau, I.W. and Vuong, L. and Borchert, F. and Movasshagi, K. and Tietze-Bürger, C. and Penack, O. and Ahn, J. and Bullinger, L. and Frentsch, M. and Na, I.K.
Frontiers in Immunology 13 : 874499. 23 May 2022

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in hematologY added value framework for hematologic malignancies: a comparative analysis of existing tools.
Cerisoli, F. and Ali, F. and Bereczky, T. and Bolaños, N. and Bullinger, L. and Dhanasiri, S. and Gallagher, J. and Pérez, S.G. and Geissler, J. and Guillevic, Y. and Harrison, K. and Naoum, A. and Portulano, C. and Rodríguez Vicente, A.E. and Schulze-Rath, R. and Gómez, G.Y. and Sanz, G. and Hernández Rivas, J.M.
Value in Health 18 May 2022 (In Press)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski, K. and Perez, A. and Iacoboni, G. and Penack, O. and Bücklein, V. and Jentzsch, L. and Mougiakakos, D. and Johnson, G. and Arciola, B. and Carpio, C. and Blumenberg, V. and Hoster, E. and Bullinger, L. and Locke, F.L. and von Bergwelt-Baildon, M. and Mackensen, A. and Bethge, W. and Barba, P. and Jain, M.D. and Subklewe, M.
Journal for ImmunoTherapy of Cancer 10 (5): e004475. 17 May 2022

Antigen presentation safeguards the integrity of the hematopoietic stem cell pool.
Hernández-Malmierca, P. and Vonficht, D. and Schnell, A. and Uckelmann, H.J. and Bollhagen, A. and Mahmoud, M.A.A. and Landua, S.L. and van der Salm, E. and Trautmann, C. and Raffel, S. and Grünschläger, F. and Lutz, R. and Ghosh, M. and Renders, S. and Correia, N. and Donato, E. and Dixon, K.O. and Hirche, C. and Andresen, C. and Robens, Cl. and Werner, P.S. and Boch, T. and Eisel, D. and Osen, W. and Pilz, F. and Przybylla, A. and Klein, C. and Buchholz, F. and Milsom, M.D. and Essers, M.A.G. and Eichmüller, S.B. and Hofmann, W.K. and Nowak, D. and Hübschmann, D. and Hundemer, M. and Thiede, C. and Bullinger, L. and Müller-Tidow, C. and Armstrong, S.A. and Trumpp, A. and Kuchroo, V.K. and Haas, S.
Cell Stem Cell 29 (5): 760-775.e10. 5 May 2022

Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Maschmeyer, G. and Bullinger, L. and Garcia-Vidal, C. and Herbrecht, R. and Maertens, J. and Menna, P. and Pagano, L. and Thiebaut-Bertrand, A. and Calandra, T.
Leukemia 36 (5): 1215-1226. May 2022

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla, G. and Radecke, C. and Frentsch, M. and Walther, W. and Stintzing, S. and Riess, H. and Bullinger, L. and Na, I.K.
OncoImmunology 11 (1): 2068109. 25 April 2022

EASIX and severe endothelial complications after CD19-directed CAR-T Cell therapy-a cohort study.
Korell, F. and Penack, O. and Mattie, M. and Schreck, N. and Benner, A. and Krzykalla, J. and Wang, Z. and Schmitt, M. and Bullinger, L. and Müller-Tidow, C. and Dreger, P. and Luft, T.
Frontiers in Immunology 13 : 877477. 8 April 2022

FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
Raschzok, N. and Stintzing, S. and Heinemann, V. and Rauch, G. and Ricke, J. and Guckenberger, M. and Kurreck, A. and Alig, A.H.S. and Stahler, A. and Bullinger, L. and Schmelzle, M. and Schöning, W. and Lurje, G. and Krenzien, F. and Haase, O. and Rau, B. and Gebauer, B. and Sauer, I.M. and Pratschke, J. and Modest, D.P.
BMC Cancer 22 (1): 359. 2 April 2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus.
Buske, C. and Dreyling, M. and Alvarez-Larrán, A. and Apperley, J. and Arcaini, L. and Besson, C. and Bullinger, L. and Corradini, P. and Della Porta, M.G. and Dimopoulos, M. and D’Sa, S. and Eich, H.T. and Foà, R. and Ghia, P. and Gomes da Silva, M. and Gribben, J. and Hajek, R. and Harrison, C. and Heuser, M. and Kiesewetter, B. and Kiladjian, J.J. and Kröger, N. and Moreau, P. and Passweg, J.R. and Peyvandi, F. and Rea, D. and Ribera, J.M. and Robak, T. and San-Miguel, J.F. and Santini, V. and Sanz, G. and Sonneveld, P. and von Lilienfeld-Toal, M. and Wendtner, C. and Pentheroudakis, G. and Passamonti, F.
ESMO Open 7 (2): 100403. April 2022

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9.
Christen, F. and Hablesreiter, R. and Hoyer, K. and Hennch, C. and Maluck-Böttcher, A. and Segler, A. and Madadi, A. and Frick, M. and Bullinger, L. and Briest, F. and Damm, F.
Leukemia 36 (4): 1102-1110. April 2022

Refining AML treatment: the role of genetics in response and resistance evaluation to new agents.
Halik, A. and Arends, C.M. and Bullinger, L. and Damm, F. and Frick, M.
Cancers 14 (7): 1689. 26 March 2022

Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome.
Ciraolo, E. and Althoff, S. and Ruß, J. and Rosnev, S. and Butze, M. and Pühl, M. and Frentsch, M. and Bullinger, L. and Na, I.K.
International Journal of Molecular Sciences 23 (6): 3207. 16 March 2022

Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Arends, C.M. and Dimitriou, S. and Stahler, A. and Hablesreiter, R. and Strzelecka, P.M. and Stein, C.M. and Tilgner, M. and Saiki, R. and Ogawa, S. and Bullinger, L. and Modest, D.P. and Stintzing, S. and Heinemann, V. and Damm, F.
Blood 139 (10): 1593-1597. 10 March 2022

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng, Y.L.D. and Ramberger, E. and Bohl, S.R. and Dolnik, A. and Steinebach, C. and Conrad, T. and Müller, S. and Popp, O. and Kull, M. and Haji, M. and Gütschow, M. and Döhner, H. and Walther, W. and Keller, U. and Bullinger, L. and Mertins, P. and Krönke, J.
Nature Communications 13 (1): 1009. 23 February 2022

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder, T.M. and Schwarzer, A. and Jayavelu, A.K. and Hsu, C.J. and Kirkpatrick, J. and Döhner, K. and Perner, F. and Eifert, T. and Huber, N. and Arreba-Tutusaus, P. and Dolnik, A. and Assi, S.A. and Nafria, M. and Jiang, L. and Dai, Y.T. and Chen, Z. and Chen, S.J. and Kellaway, S.G. and Ptasinska, A. and Ng, E.S. and Stanley, E.G. and Elefanty, A.G. and Buschbeck, M. and Bierhoff, H. and Brodt, S. and Matziolis, G. and Fischer, K.D. and Hochhaus, A. and Chen, C.W. and Heidenreich, O. and Mann, M. and Lane, S.W. and Bullinger, L. and Ori, A. and von Eyss, B. and Bonifer, C. and Heidel, F.
Blood 139 (7): 1080-1097. 17 February 2022

Acute left ventricular insufficiency in a Burkitt Lymphoma patient with myocardial involvement and extensive local tumor cell lysis: a case report.
Schmiester, M. and Tranter, E. and Lorusso, A. and Blaschke, F. and Geisel, D. and Bullinger, L. and Damm, F. and Na, I.K.
BMC Cardiovascular Disorders 22 (1): 31. 4 February 2022

CEBPA mutations in AML: site matters.
Bullinger, L.
Blood 139 (1): 6-7. 6 January 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S. and Bittner, A. and Frick, M. and Kase, J. and Hoffmann, J. and Trenker, C. and Keller, U. and Bogner, C. and Hüttmann, A. and Dürig, J. and Janz, M. and Mathas, S. and Marks, R. and Krohn, U. and Na, I.K. and Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker, F.G. and Du, L. and Luck, T.J. and Benner, A. and Krzykalla, J. and Gathmann, I. and Voso, M.T. and Amadori, S. and Prior, T.W. and Brandwein, J.M. and Appelbaum, F.R. and Medeiros, B.C. and Tallman, M.S. and Savoie, L. and Sierra, J. and Pallaud, C. and Sanz, M.A. and Jansen, J.H. and Niederwieser, D. and Fischer, T. and Ehninger, G. and Heuser, M. and Ganser, A. and Bullinger, L. and Larson, R.A. and Bloomfield, C.D. and Stone, R.M. and Döhner, H. and Thiede, C. and Döhner, K.
Leukemia 36 (1): 90-99. January 2022


Survey of long-term experiences of sperm cryopreservation in oncological and non-oncological patients: usage and reproductive outcomes of a large monocentric cohort.
Lackamp, N. and Wilkemeyer, I. and Jelas, I. and Keller, U. and Bullinger, L. and Stintzing, S. and le Coutre, P.
Frontiers in Oncology 11 : 772809. 5 November 2021

Netboost: boosting-supported network analysis improves high-dimensional omics prediction in acute myeloid leukemia and Huntington's disease.
Schlosser, P. and Knaus, J. and Schmutz, M. and Döhner, K. and Plass, C. and Bullinger, L. and Claus, R. and Binder, H. and Lübbert, M. and Schumacher, M.
IEEE/ACM Transactions on Computational Biology and Bioinformatics 18 (6): 2635-2648. 1 November 2021

Survivin’ acute myeloid leukaemia - a personalised target for inv(16) patients.
Greiner, J. and Brown, E. and Bullinger, L. and Hills, R.K. and Morris, V. and Döhner, H. and Mills, K.I. and Guinn, B.A.
International Journal of Molecular Sciences 22 (19): 10482. 1 October 2021

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Bloehdorn, J. and Braun, A. and Taylor-Weiner, A. and Jebaraj, B.M.C. and Robrecht, S. and Krzykalla, J. and Pan, H. and Giza, A. and Akylzhanova, G. and Holzmann, K. and Scheffold, A. and Johnston, H.E. and Yeh, R.F. and Klymenko, T. and Tausch, E. and Eichhorst, B. and Bullinger, L. and Fischer, K. and Weisser, M. and Robak, T. and Schneider, C. and Gribben, J. and Dahal, L.N. and Carter, M.J. and Elemento, O. and Landau, D.A. and Neuberg, D.S. and Cragg, M.S. and Benner, A. and Hallek, M. and Wu, C.J. and Döhner, H. and Stilgenbauer, S. and Mertens, D.
Nature Communications 12 (1): 5395. 13 September 2021

58/w mit zunehmender psychomotorischer Verlangsamung und Zephalgien [58/f with increasing psychomotor retardation and headache].
Onken, J.S. and Bullinger, L.
Onkologe 27 : 79-84. September 2021

CD4+ T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation.
Heck, C. and Steiner, S. and Kaebisch, E.M. and Frentsch, M. and Wittenbecher, F. and Scheibenbogen, C. and Hanitsch, L.G. and Nogai, A. and le Coutre, P. and Bullinger, L. and Blau, I.W. and Na, I.K.
Frontiers in Immunology 12 : 736137. September 2021

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
Rapaport, F. and Neelamraju, Y. and Baslan, T. and Hassane, D. and Gruszczynska, A. and de Massy, M.R. and Farnoud, N. and Haddox, S. and Lee, T. and Medina-Martinez, J. and Sheridan, C. and Thurmond, A. and Becker, M. and Bekiranov, S. and Carroll, M. and Moses Murdock, H. and Valk, P.J.M. and Bullinger, L. and D’Andrea, R. and Lowe, S.W. and Neuberg, D. and Levine, R.L. and Melnick, A. and Garrett-Bakelman, F.E.
Leukemia 35 (9): 2688-2692. September 2021

The EHA Research Roadmap: Malignant Myeloid Diseases.
Döhner, H. and Malcovati, L. and Ossenkoppele, G.J. and Hochhaus, A. and Maria Vannucchi, A. and Bullinger, L. and Cervantes, F. and Craddock, C. and de Witte, T. and Döhner, K. and Dombret, H. and Fenaux, P. and Geissler, J. and Germing, U. and Guilhot, F. and Harrison, C. and Hellström-Lindberg, E. and Passamonti, F. and Sierra, J. and Skoda, R. and Wierzbowska, A.
HemaSphere 5 (9): e635. September 2021

COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab.
Dimai, S. and Semmler, L. and Prabhu, A. and Stachelscheid, H. and Huettemeister, J. and Klaucke, S.C. and Lacour, P. and Blaschke, F. and Kruse, J. and Parwani, A. and Boldt, L.H. and Bullinger, L. and Pieske, B.M. and Heinzel, F.R. and Hohendanner, F.
PLoS ONE 16 (8): e0255976. 19 August 2021

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch, M.E. and Kast, R.E. and Karpel-Massler, G. and Mayer, B. and Zolk, O. and Schmitz, B. and Scheuerle, A. and Maier, L. and Bullinger, L. and Mayer-Steinacker, R. and Schmidt, C. and Zeiler, K. and Elshaer, Z. and Panther, P. and Schmelzle, B. and Hallmen, A. and Dwucet, A. and Siegelin, M.D. and Westhoff, M.A. and Beckers, K. and Bouche, G. and Heiland, T.
Neuro-Oncology Advances 3 (1): vdab075. 7 August 2021

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.
Bittner, A. and Radke, J. and Eurich, D. and Wiener, E. and Denker, S. and Anagnostopoulos, I. and Na, I.K. and Heppner, F.L. and Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 62 (8): 2026-2029. August 2021

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, N. and Duell, J. and Fitzgerald, D. and Kerkhoff, A. and Noerenberg, D. and Kaebisch, E. and Acker, F. and Fuhrmann, S. and Leng, C. and Welslau, M. and Chemnitz, J. and Middeke, J.M. and Weber, T. and Holtick, U. and Trappe, R. and Pfannes, R. and Liersch, R. and Spoer, C. and Fuxius, S. and Gebauer, N. and Caillé, L. and Geer, T. and Koenecke, C. and Keller, U. and Claus, R. and Mougiakakos, D. and Mayer, S. and Huettmann, A. and Pott, C. and Trummer, A. and Wulf, G. and Brunnberg, U. and Bullinger, L. and Hess, G. and Mueller-Tidow, C. and Glass, B. and Lenz, G. and Dreger, P. and Dietrich, S.
Blood Advances 5 (13): 2707-2716. 13 July 2021

Early bilirubinemia after allogeneic stem cell transplantation - an endothelial complication.
Dai, H. and Penack, O. and Radujkovic, A. and Schult, D. and Majer-Lauterbach, J. and Blau, I.W. and Bullinger, L. and Jiang, S. and Müller-Tidow, C. and Dreger, P. and Luft, T.
Bone Marrow Transplantation 56 (7): 1573-1583. July 2021

Genome sequencing in myeloid cancers.
Dolnik, A. and Schrezenmeier, J. and Bullinger, L.
New England Journal of Medicine 384 (25): e106. 24 June 2021

Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda, S. and Heimann, A. and Obermayer, B. and Ciraolo, E. and Althoff, S. and Ruß, J. and Grunert, C. and Busse, A. and Bullinger, L. and Pezzutto, A. and Blankenstein, T. and Beule, D. and Na, I.K.
International Journal of Cancer 148 (12): 3097-3110. 15 June 2021

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock, L.K. and Dolnik, A. and Cocciardi, S. and Sträng, E. and Theis, F. and Jahn, N. and Panina, E. and Blätte, T.J. and Herzig, J.K. and Skambraks, S. and Rücker, F.G. and Gaidzik, V.I. and Paschka, P. and Fiedler, W. and Salih, H.R. and Wulf, G.G. and Schroeder, T. and Lübbert, M. and Schlenk, R.F. and Thol, F. and Heuser, M. and Larson, R.A. and Ganser, A. and Stunnenberg, H.G. and Minucci, S. and Stone, R.M. and Bloomfield, C.D. and Döhner, H. and Döhner, K. and Bullinger, L.
Blood 137 (22): 3093-3104. 3 June 2021

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl, S.R. and Schmalbrock, L.K. and Bauhuf, I. and Meyer, T. and Dolnik, A. and Szyska, M. and Blätte, T.J. and Knödler, S. and Röhner, L. and Miller, D. and Kull, M. and Langer, C. and Döhner, H. and Letai, A. and Damm, F. and Heckl, D. and Bullinger, L. and Krönke, J.
Blood Advances 5 (9): 2391-2402. 11 May 2021

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser, M. and Heida, B. and Büttner, K. and Wienecke, C.P. and Teich, K. and Funke, C. and Brandes, M. and Klement, P. and Liebich, A. and Wichmann, M. and Neziri, B. and Chaturvedi, A. and Kloos, A. and Mintzas, K. and Gaidzik, V.I. and Paschka, P. and Bullinger, L. and Fiedler, W. and Heim, A. and Puppe, W. and Krauter, J. and Döhner, K. and Döhner, H. and Ganser, A. and Stadler, M. and Hambach, L. and Gabdoulline, R. and Thol, F.
Blood Advances 5 (9): 2294-2304. 11 May 2021

Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades.
Ihlow, J. and Gross, S. and Neuendorff, N.R. and Busack, L. and Herneth, A. and Singh, A. and Schwarz, M. and Flörcken, A. and Anagnostopoulos, I. and Türkmen, S. and Burmeister, T. and Blau, I.W. and Bullinger, L. and Westermann, J.
Journal of Geriatric Oncology 12 (4): 540-549. May 2021

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.
Giacopelli, B. and Wang, M. and Cleary, A. and Wu, Y.Z. and Schultz, A.R. and Schmutz, M. and Blachly, J.S. and Eisfeld, A.K. and Mundy-Bosse, B. and Vosberg, S. and Greif, P.A. and Claus, R. and Bullinger, L. and Garzon, R. and Coombes, K.R. and Bloomfield, C.D. and Druker, B.J. and Tyner, J.W. and Byrd, J.C. and Oakes, C.C.
Genome Research 31 (5): 747-761. May 2021

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: results from the CONKO-005 trial.
Hoyer, K. and Hablesreiter, R. and Inoue, Y. and Yoshida, K. and Briest, F. and Christen, F. and Kakiuchi, N. and Yoshizato, T. and Shiozawa, Y. and Shiraishi, Y. and Striefler, J.K. and Bischoff, S. and Lohneis, P. and Putter, H. and Blau, O. and Keilholz, U. and Bullinger, L. and Pelzer, U. and Hummel, M. and Riess, H. and Ogawa, S. and Sinn, M. and Damm, F.
EBioMedicine 66 : 103327. April 2021

Deregulated expression of circular RNAs in acute myeloid leukemia.
Lux, S. and Blätte, T.J. and Gillissen, B. and Richter, A. and Cocciardi, S. and Skambraks, S. and Schwarz, K. and Schrezenmeier, H. and Döhner, H. and Döhner, K. and Dolnik, A. and Bullinger, L.
Blood Advances 5 (5): 1490-1503. 9 March 2021

NEMHESYS - European perspective on the implementation of next-generation sequencing into clinical diagnostics.
Serramito-Gómez, I. and Clarke, K.M. and Rodríguez-Vicente, A.E. and McGimpsey, J.E. and Abáigar, M. and Díez, C.B. and Benito, R. and Bullinger, L. and Mills, K.I. and Hernández Rivas, J.M.
HemaSphere 5 (3): e541. March 2021

B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased.
Ihlow, J. and Michaelis, E. and Greuel, S. and Heynol, V. and Lehmann, A. and Radbruch, H. and Meinhardt, J. and Miller, F. and Herbst, H. and Corman, V.M. and Westermann, J. and Bullinger, L. and Horst, D. and von Brünneck, A.C. and Elezkurtaj, S.
International Journal of Infectious Diseases 103 : 628-635. February 2021

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis.
Brandes, F. and Striefler, J.K. and Dörr, A. and Schmiester, M. and Märdian, S. and Koulaxouzidis, G. and Kaul, D. and Behzadi, A. and Thuss-Patience, P. and Ahn, J. and Pelzer, U. and Bullinger, L. and Flörcken, A.
BMC Palliative Care 20 (1): 16. 14 January 2021

Gene expression profiling predicts sensitivity of chronic lymphocytic leukemia cells to dasatinib.
Blätte, T.J. and Machnicki, M.M. and Glodkowska-Mrowka, E. and Dolnik, A. and Karp, M. and Karczmarczyk, A. and Giannopoulos, K. and Bullinger, L. and Stoklosa, T.
HemaSphere 5 (1): e514. January 2021

TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester, M. and Dolnik, A. and Kornak, U. and Pfitzner, B. and Hummel, M. and Treue, D. and Hartmann, A. and Agaimy, A. and Weyerer, V. and Lekaj, A. and Brakemeier, S. and Peters, R. and Öllinger, R. and Märdian, S. and Bullinger, L. and Striefler, J.K. and Flörcken, A.
Journal of Pathology Clinical Research 7 (1): 3-9. January 2021

Genomic landscape and clonal evolution of AML.
Noerenberg, D. and Damm, F. and Bullinger, L.
In: Acute Myeloid Leukemia. Hematologic Malignancies . Springer, Cham, 103-118. ISBN 978-3-030-72675-1 2021


Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer, S. and Weber, D. and Corbacioglu, A. and Gaidzik, V.I. and Paschka, P. and Krönke, J. and Theis, F. and Rücker, F.G. and Teleanu, M.V. and Panina, E. and Jahn, N. and Herzig, J. and Kubanek, L. and Schrade, A. and Göhring, G. and Fiedler, W. and Kindler, T and Schroeder, T. and Mayer, K.T. and Lübbert, M. and Wattad, M. and Götze, K.S. and Horst, H.A. and Koller, E. and Wulf, G. and Schleicher, J. and Bentz, M. and Krauter, J. and Bullinger, L. and Krzykalla, J. and Benner, A. and Schlenk, R.F. and Thol, F. and Heuser, M. and Ganser, A. and Döhner, H and Döhner, K.
Blood 136 (26): 3041-3050. 24 December 2020

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn, N. and Terzer, T. and Sträng, E. and Dolnik, A. and Cocciardi, S. and Panina, E. and Corbacioglu, A. and Herzig, J. and Weber, D. and Schrade, A. and Götze, K. and Schröder, T. and Lübbert, M. and Wellnitz, D. and Koller, E. and Schlenk, R.F. and Gaidzik, V.I. and Paschka, P. and Rücker, F.G. and Heuser, M. and Thol, F. and Ganser, A. and Benner, A. and Döhner, H. and Bullinger, L. and Döhner, K.
Blood Advances 4 (24): 6342-6352. 22 December 2020

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Jayavelu, A.K. and Schnöder, T.M. and Perner, F. and Herzog, C. and Meiler, A. and Krishnamoorthy, G. and Huber, N. and Mohr, J. and Edelmann-Stephan, B. and Austin, R. and Brandt, S. and Palandri, F. and Schröder, N. and Isermann, B. and Edlich, F. and Sinha, A.U. and Ungelenk, M. and Hübner, C.A. and Zeiser, R. and Rahmig, S. and Waskow, C. and Coldham, I. and Ernst, T. and Hochhaus, A. and Jilg, S. and Jost, P.J. and Mullally, A. and Bullinger, L. and Mertens, P.R. and Lane, S.W. and Mann, M. and Heidel, F.H.
Nature 588 (7836): 157-163. 3 December 2020

A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial.
Janssen, M. and Schäkel, U. and Djuka Fokou, C. and Krisam, J. and Stermann, J. and Kriegsmann, K. and Haberbosch, I. and Novotny, J.P. and Weber, S. and Vehreschild, M. and Bornhäuser, M. and Bullinger, L. and Schmitt, M. and Liebregts, T. and Dreger, P. and Lorenz, H.M. and Plaszczyca, A. and Bartenschlager, R. and Müller, B. and Kräusslich, H.G. and Halama, N. and Jäger, D. and Schlenk, R.F. and Leo, A. and Meuer, S. and Weigand, M.A. and Motsch, J. and Merle, U. and Denkinger, C.M. and Müller-Tidow, C.
Trials 21 (1): 828. 6 October 2020

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Tausch, E. and Beck, P. and Schlenk, R.F. and Jebaraj, B.M.C. and Dolnik, A. and Yosifov, D.Y. and Hillmen, P. and Offner, F. and Janssens, A. and Babu, K.G. and Grosicki, S. and Mayer, J. and Panagiotidis, P. and McKeown, A. and Gupta, I.V. and Skorupa, A. and Pallaud, C. and Bullinger, L. and Mertens, D. and Döhner, H. and Stilgenbauer, S.
Haematologica 105 (10): 2440-2447. October 2020

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells.
Raffel, S. and Klimmeck, D. and Falcone, M. and Demir, A. and Pouya, A. and Zeisberger, P. and Lutz, C. and Tinelli, M. and Bischel, O. and Bullinger, L. and Thiede, C. and Flörcken, A. and Westermann, J. and Ehninger, G. and Ho, A.D. and Müller-Tidow, C. and Gu, Z. and Herrmann, C. and Krijgsveld, J. and Trumpp, A. and Hansson, J.
Blood 136 (13): 1507-1519. 24 September 2020

Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
Yusuf, R.Z. and Saez, B. and Sharda, A. and van Gastel, N. and Yu, V.W.C. and Baryawno, N. and Scadden, E.W. and Acharya, S. and Chattophadhyay, S. and Huang, C. and Viswanathan, V. and S'aulis, D. and Cobert, J. and Sykes, D.B. and Keibler, M.A. and Das, S. and Hutchinson, J.N. and Churchill, M. and Mukherjee, S. and Lee, D. and Mercier, F. and Doench, J. and Bullinger, L. and Logan, D.J. and Schreiber, S. and Stephanopoulos, G. and Rizzo, W.B. and Scadden, D.T.
Blood 136 (11): 1303-1316. 10 September 2020

Endothelial damage and dysfunction in acute graft-versus-host disease.
Cordes, S. and Mokhtari, Z. and Bartosova, M. and Mertlitz, S. and Riesner, K. and Shi, Y. and Mengwasser, J. and Kalupa, M. and McGeary, A. and Schleifenbaum, J. and Schrezenmeier, J. and Bullinger, L. and Diaz-Ricart, M. and Palomo, M. and Carrreras, E. and Beutel, G. and Schmitt, C.P. and Beilhack, A. and Penack, O.
Haematologica 106 (8): 2147-2160. 1 August 2020

Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber, C. and Correia, N. and Trumpp, A. and Rieger, M.A. and Dolnik, A. and Bullinger, L. and Roeder, I. and Seifert, M.
Scientific Reports 10 (1): 12761. 29 July 2020

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.
Jiang, S. and Penack, O. and Terzer, T. and Schult, D. and Majer-Lauterbach, J. and Radujkovic, A. and Blau, I.W. and Bullinger, L. and Müller-Tidow, C. and Dreger, P. and Luft, T.
Haematologica 106 (2): 446-453. February 2020

This list was generated on Sun Sep 25 02:20:45 2022 CEST.
Open Access
MDC Library